Phosphatidylserine-expressing cell by-products in transfusion: A pro-inflammatory or an anti-inflammatory effect?
Labile blood products contain phosphatidylserine-expressing cell dusts, including apoptotic cells and microparticles. These cell by-products are produced during blood product process or storage and derived from the cells of interest that exert a therapeutic effect (red blood cells or platelets). Alternatively, phosphatidylserine-expressing cell dusts may also derived from contaminating cells, such as leukocytes, or may be already present in plasma, such as platelet-derived microparticles. These cell by-products present in labile blood products can be responsible for transfusion-induced immunomodulation leading to either transfusion-related acute lung injury (TRALI) or increased occurrence of post-transfusion infections or cancer relapse. In this review, we report data from the literature and our laboratory dealing with interactions between antigen-presenting cells and phosphatidylserine-expressing cell dusts, including apoptotic leukocytes and blood cell-derived microparticles. Then, we discuss how these phosphatidylserine-expressing cell by-products may influence transfusion.
Inserm, UMR1098, BP 1937, 25020 Besançon cedex, France. philippe.saas@efs.sante.fr
P
P
Saas
F
F
Angelot
L
L
Bardiaux
E
E
Seilles
F
F
Garnache-Ottou
S
S
Perruche
D055252:Cell-Derived Microparticles / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000209:etiology* / Q000276:immunology*; D010718:Phosphatidylserines / Q000096:biosynthesis*; D065227:Transfusion Reaction
D010718:Phosphatidylserines